NASDAQ:FBIO - Fortress Biotech Stock Price, Price Target & More

$4.19 -0.11 (-2.56 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$4.30
Today's Range$4.13 - $4.31
52-Week Range$3.13 - $5.54
Volume85,408 shs
Average Volume157,768 shs
Market Capitalization$223.85 million
P/E RatioN/A
Dividend YieldN/A
Beta0.23

About Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech logoFortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company develops CNDO-109, a lysate that treats cancer-related and other conditions; tramadol HCl for managing postoperative pain; CAEL-101 for the treatment of amyloid light chain amyloidosis; and CEVA101 for severe traumatic brain injury in children and adults in the United States. It also develops CK-301 for treating patients with non-small cell lung cancer (NSCLC); CK-101 for the treatment of patients with epidermal growth factor receptor mutation-positive NSCLC; and antibodies that target glucocorticoid-induced TNFR-related protein and carbonic anhydrase IX, as well as anti-cancer agents that inhibit bromodomain and extra-terminal proteins, and poly polymerase. In addition, the company develops CUTX-101 for treating Menkes disease; preclinical adeno-associated virus gene therapies for treating mucopolysaccharidosis type 1, dysferlinopathies, and corneal transplant rejection; Triplex, which is in Phase II clinical study for preventing and treating cytomegalovirus (CMV); and Pentamer, a vaccine drug candidate for preventing CMV. Further, it offers Targadox, a tablet for severe acne; Luxamend wound cream; Ceracade for treating dry skin conditions; Triderm for treating eczema, dermatitis, allergies, and rash; and chimeric antigen receptor and engineered T cell therapies across various cancers. Additionally, it provides retail brokerage and wealth management services to high net worth individual and institutional clients; investment banking, merger and acquisition, and advisory services to micro, small, and mid-cap high growth companies; trades in securities; liquidity services; and tax preparation, fixed insurance sales, and licensed mortgage brokerage services. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Receive FBIO News and Ratings via Email

Sign-up to receive the latest news and ratings for FBIO and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:FBIO
CUSIP21976U10
Phone781-652-4500

Debt

Debt-to-Equity Ratio0.44%
Current Ratio2.72%
Quick Ratio2.71%

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$187.58 million
Price / Sales1.15
Cash FlowN/A
Price / CashN/A
Book Value$2.38 per share
Price / Book1.76

Profitability

EPS (Most Recent Fiscal Year)($1.61)
Net Income$-66,870,000.00
Net Margins-46.69%
Return on Equity-51.57%
Return on Assets-28.08%

Miscellaneous

Employees68
Outstanding Shares51,340,000

How to Become a New Pot Stock Millionaire

Fortress Biotech (NASDAQ:FBIO) Frequently Asked Questions

What is Fortress Biotech's stock symbol?

Fortress Biotech trades on the NASDAQ under the ticker symbol "FBIO."

How were Fortress Biotech's earnings last quarter?

Fortress Biotech (NASDAQ:FBIO) announced its quarterly earnings data on Thursday, November, 9th. The biopharmaceutical company reported ($0.67) EPS for the quarter, missing the Zacks' consensus estimate of ($0.43) by $0.24. The biopharmaceutical company earned $46.89 million during the quarter, compared to analysts' expectations of $50.75 million. Fortress Biotech had a negative net margin of 46.69% and a negative return on equity of 51.57%. The firm's quarterly revenue was up 4709.2% compared to the same quarter last year. View Fortress Biotech's Earnings History.

When is Fortress Biotech's next earnings date?

Fortress Biotech is scheduled to release their next quarterly earnings announcement on Tuesday, May, 8th 2018. View Earnings Estimates for Fortress Biotech.

What price target have analysts set for FBIO?

4 equities research analysts have issued 1 year price objectives for Fortress Biotech's stock. Their forecasts range from $10.00 to $11.00. On average, they anticipate Fortress Biotech's stock price to reach $10.75 in the next year. View Analyst Ratings for Fortress Biotech.

What are Wall Street analysts saying about Fortress Biotech stock?

Here are some recent quotes from research analysts about Fortress Biotech stock:
  • 1. According to Zacks Investment Research, "Fortress Biotech, Inc. is a biopharmaceutical company. The company is engaged in acquiring, developing and commercializing novel pharmaceutical and biotechnology products. Fortress Biotech, Inc., formerly known as Coronado Biosciences, Inc., is based in NEW YORK, United States. " (2/19/2018)
  • 2. FBR & Co analysts commented, "On May 10, Fortress reported 1Q17 results. The company did not host a conference call, but we had a chance to catch up with the CEO. We note that Fortress made great progress in terms of advancing its pipeline in 2017. Recent company highlights include the launch of two additional subsidiaries in the quarter, Caelum Biosciences and Cyprium Therapeutics, thereby broadening the company pipeline to include amyloid light chain (AL) amyloidosis and Menkes disease indications. We expect the company to continue to advance its pipeline and explore additional opportunities to strengthen its subsidiary company portfolio for the rest of 2017." (5/12/2017)

Who are some of Fortress Biotech's key competitors?

Who are Fortress Biotech's key executives?

Fortress Biotech's management team includes the folowing people:
  • Dr. Lindsay Allan Rosenwald, Chairman, CEO & Pres (Age 63)
  • Mr. George C. Avgerinos, Sr. VP of Biologics Operations (Age 64)
  • Mr. Michael S. Weiss, Exec. Vice Chairman of Strategic Devel. & Director (Age 52)
  • Ms. Robyn M. Hunter, Chief Financial Officer (Age 56)
  • Mr. Timothy M. Hillman, VP of Operations

Has Fortress Biotech been receiving favorable news coverage?

News stories about FBIO stock have been trending somewhat positive recently, according to Accern Sentiment. The research firm ranks the sentiment of media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fortress Biotech earned a news impact score of 0.22 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 46.94 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the stock's share price in the next few days.

How do I buy shares of Fortress Biotech?

Shares of FBIO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Fortress Biotech's stock price today?

One share of FBIO stock can currently be purchased for approximately $4.19.

How big of a company is Fortress Biotech?

Fortress Biotech has a market capitalization of $223.85 million and generates $187.58 million in revenue each year. The biopharmaceutical company earns $-66,870,000.00 in net income (profit) each year or ($1.61) on an earnings per share basis. Fortress Biotech employs 68 workers across the globe.

How can I contact Fortress Biotech?

Fortress Biotech's mailing address is 2 GANSEVOORT STREET 9TH FLOOR, NEW YORK NY, 10014. The biopharmaceutical company can be reached via phone at 781-652-4500 or via email at [email protected]


MarketBeat Community Rating for Fortress Biotech (FBIO)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  163 (Vote Outperform)
Underperform Votes:  132 (Vote Underperform)
Total Votes:  295
MarketBeat's community ratings are surveys of what our community members think about Fortress Biotech and other stocks. Vote "Outperform" if you believe FBIO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe FBIO will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Fortress Biotech (NASDAQ:FBIO) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Fortress Biotech in the last 12 months. Their average twelve-month price target is $10.75, suggesting that the stock has a possible upside of 156.56%. The high price target for FBIO is $11.00 and the low price target for FBIO is $10.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 3.003.003.003.00
Ratings Breakdown: 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $10.75$10.80$11.00$11.00
Price Target Upside: 156.56% upside109.71% upside175.69% upside171.60% upside

Fortress Biotech (NASDAQ:FBIO) Consensus Price Target History

Price Target History for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ:FBIO) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/27/2018HC WainwrightSet Price TargetBuy$11.00LowView Rating Details
2/28/2018B. RileyInitiated CoverageBuy -> Buy$10.00HighView Rating Details
7/11/2017Rodman & RenshawInitiated CoverageBuy -> Buy$11.00LowView Rating Details
7/4/2017FBR & CoReiterated RatingBuyMediumView Rating Details
3/22/2017JMP SecuritiesInitiated CoverageMkt Outperform -> Outperform$11.00MediumView Rating Details
10/3/2016Roth CapitalInitiated CoverageBuy$9.00N/AView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Fortress Biotech (NASDAQ:FBIO) Earnings History and Estimates Chart

Earnings by Quarter for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ:FBIO) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.88 EPS
Next Year EPS Consensus Estimate: $-1.65 EPS

Fortress Biotech (NASDAQ FBIO) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018N/AView Earnings Details
11/9/2017Q3 2017($0.43)($0.67)$50.75 million$46.89 millionViewN/AView Earnings Details
8/9/2017Q2 2017($0.32)($0.43)$44.10 million$50.70 millionViewN/AView Earnings Details
5/10/2017Q1 2017($0.36)($0.30)$47.04 million$2.78 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.43)$47.93 million$14.41 millionViewN/AView Earnings Details
11/9/2016Q3 2016($0.20)($0.32)$29.15 million$0.98 millionViewN/AView Earnings Details
8/9/2016Q2($0.29)($0.31)$1.07 million$2.23 millionViewN/AView Earnings Details
5/10/2016Q1($0.31)$0.66 millionViewN/AView Earnings Details
3/15/2016Q4($0.09)($0.31)$0.34 millionViewN/AView Earnings Details
11/9/2015Q315($0.13)($0.46)$0.03 millionViewN/AView Earnings Details
8/10/2015Q2($0.16)ViewN/AView Earnings Details
5/11/2015Q1($0.31)ViewN/AView Earnings Details
3/16/2015Q414($0.10)ViewN/AView Earnings Details
11/6/2014Q3 2014($0.13)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.17)($0.13)ViewN/AView Earnings Details
5/12/2014Q114($0.18)($0.21)ViewN/AView Earnings Details
3/14/2014Q413($0.22)($0.27)ViewN/AView Earnings Details
11/1/2013Q313($0.31)($0.24)ViewN/AView Earnings Details
8/5/2013Q213($0.31)($0.38)ViewN/AView Earnings Details
5/8/2013Q1 2013($0.30)($0.35)ViewN/AView Earnings Details
3/14/2013Q4 2012($0.27)($0.36)ViewN/AView Earnings Details
11/14/2012Q312($0.28)($0.24)ViewN/AView Earnings Details
8/8/2012Q2 2012($0.35)($0.34)ViewN/AView Earnings Details
5/15/2012Q1 2012($0.31)($0.35)ViewN/AView Earnings Details
3/29/2012Q4 2011($0.33)($0.40)ViewN/AView Earnings Details
11/14/2011Q3 2011($0.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Fortress Biotech (NASDAQ:FBIO) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Fortress Biotech (NASDAQ FBIO) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 33.30%
Institutional Ownership Percentage: 11.75%
Insider Trading History for Fortress Biotech (NASDAQ:FBIO)
Institutional Ownership by Quarter for Fortress Biotech (NASDAQ:FBIO)

Fortress Biotech (NASDAQ FBIO) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
12/14/2017George AvgerinosSVPSell12,000$3.55$42,600.00352,495View SEC Filing  
12/12/2017George AvgerinosSVPSell25,593$3.59$91,878.87409,088View SEC Filing  
11/6/2017Lindsay A Md RosenwaldCEOBuy40,000$25.00$1,000,000.0040,000View SEC Filing  
9/16/2016George AvgerinosSVPSell48,912$2.55$124,725.60293,000View SEC Filing  
12/1/2014Lucy LuCFOBuy5,000$1.45$7,250.00View SEC Filing  
11/6/2014Lindsay A Md RosenwaldCEOBuy150,000$1.61$241,500.00View SEC Filing  
11/6/2014Malcolm HoenleinDirectorBuy25,000$1.61$40,250.00View SEC Filing  
11/6/2014Michael S WeissMajor ShareholderBuy1,000,000$1.61$1,610,000.00View SEC Filing  
6/2/2014Lucy LuCFOBuy5,000$1.37$6,850.00View SEC Filing  
4/22/2014Kevin HorganInsiderSell47,566$1.89$89,899.74View SEC Filing  
4/21/2014Kevin HorganInsiderSell19,000$1.81$34,390.00View SEC Filing  
8/21/2013J Jay LobellDirectorBuy5,000$7.37$36,850.00View SEC Filing  
7/17/2013Lucy LuCFOBuy4,545$7.90$35,905.50View SEC Filing  
6/20/2013J Jay LobellDirectorBuy10,000$7.62$76,200.00View SEC Filing  
5/31/2013Dale RitterCAOBuy1,503$3.88$5,831.64View SEC Filing  
5/31/2013Lucy LuCFOBuy4,979$3.88$19,318.52View SEC Filing  
5/31/2013Noah D BeermanCOOBuy5,000$3.88$19,400.00View SEC Filing  
1/14/2013Harlan F WeismanCEOBuy20,000$5.71$114,200.00View SEC Filing  
11/30/2012Glenn L Md CooperInsiderBuy3,811$4.02$15,320.22View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Fortress Biotech (NASDAQ FBIO) News Headlines

Source:
DateHeadline
Fortress Biotech (FBIO) Given Buy Rating at FBR & CoFortress Biotech (FBIO) Given Buy Rating at FBR & Co
www.americanbankingnews.com - April 19 at 10:46 PM
Fortress Biotech (FBIO) Now Covered by Analysts at Rodman & RenshawFortress Biotech (FBIO) Now Covered by Analysts at Rodman & Renshaw
www.americanbankingnews.com - April 19 at 4:00 PM
HC Wainwright Reiterates $11.00 Price Target for Fortress Biotech (FBIO)HC Wainwright Reiterates $11.00 Price Target for Fortress Biotech (FBIO)
www.americanbankingnews.com - April 19 at 12:16 PM
Fortress Biotech (FBIO) Given Consensus Recommendation of "Buy" by AnalystsFortress Biotech (FBIO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - April 12 at 8:49 AM
HC Wainwright Analysts Give Fortress Biotech (FBIO) a $11.00 Price TargetHC Wainwright Analysts Give Fortress Biotech (FBIO) a $11.00 Price Target
www.americanbankingnews.com - April 10 at 11:38 PM
Fortress Biotech (FBIO) Lowered to Sell at ValuEngineFortress Biotech (FBIO) Lowered to Sell at ValuEngine
www.americanbankingnews.com - April 8 at 9:37 AM
Fortress Biotech (FBIO) Upgraded by Zacks Investment Research to "Hold"Fortress Biotech (FBIO) Upgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - April 7 at 3:53 PM
Fortress Biotech (FBIO) Lifted to Buy at ValuEngineFortress Biotech (FBIO) Lifted to Buy at ValuEngine
www.americanbankingnews.com - April 5 at 1:57 PM
Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate HighlightsMustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 29 at 4:39 PM
Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for ...Avenue Therapeutics Receives Notices of Allowance for Patent Applications Covering Methods of Administration for ...
globenewswire.com - March 28 at 9:10 AM
Fortress Biotech (FBIO) Reports Updated Phase 1b Data Presented at 16th International Symposium on AmyloidosisFortress Biotech (FBIO) Reports Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis
www.streetinsider.com - March 27 at 4:46 PM
Fortress Biotech (FBIO) Given a $11.00 Price Target at HC WainwrightFortress Biotech (FBIO) Given a $11.00 Price Target at HC Wainwright
www.americanbankingnews.com - March 27 at 1:16 PM
Caelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on AmyloidosisCaelum Biosciences Announces Updated Phase 1b Data Presented at 16th International Symposium on Amyloidosis
finance.yahoo.com - March 27 at 9:11 AM
Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th ... - GlobeNewswire (press release)Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th ... - GlobeNewswire (press release)
globenewswire.com - March 21 at 9:47 AM
Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301Checkpoint Therapeutics Initiates Dose Expansion Portion of Phase 1 Trial of Anti-PD-L1 Antibody CK-301
finance.yahoo.com - March 21 at 9:47 AM
Caelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on AmyloidosisCaelum Biosciences Announces Clinical Data on CAEL-101 in AL Amyloidosis Selected for Oral Presentation at 16th International Symposium on Amyloidosis
finance.yahoo.com - March 21 at 9:47 AM
Mustang Bio to Present at CAR-T Congress USA - NASDAQ.com - NasdaqMustang Bio to Present at CAR-T Congress USA - NASDAQ.com - Nasdaq
www.nasdaq.com - March 20 at 9:14 AM
Mustang Bio to Present at CAR-T Congress USA - GlobeNewswire (press release)Mustang Bio to Present at CAR-T Congress USA - GlobeNewswire (press release)
globenewswire.com - March 20 at 9:14 AM
Fortress Biotech Inc (FBIO) Given Consensus Rating of "Buy" by AnalystsFortress Biotech Inc (FBIO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - March 18 at 9:11 AM
-$0.46 Earnings Per Share Expected for Fortress Biotech Inc (FBIO) This Quarter-$0.46 Earnings Per Share Expected for Fortress Biotech Inc (FBIO) This Quarter
www.americanbankingnews.com - March 18 at 8:46 AM
Mustang Bio Announces Key Leadership Appointments - GlobeNewswire (press release)Mustang Bio Announces Key Leadership Appointments - GlobeNewswire (press release)
globenewswire.com - March 17 at 4:49 PM
Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights - GlobeNewswire (press release)
globenewswire.com - March 17 at 4:49 PM
Fortress Biotech (FBIO) Given Buy Rating at HC WainwrightFortress Biotech (FBIO) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - March 16 at 2:10 PM
Cardiome Pharma (CRME) vs. Fortress Biotech (FBIO) Critical ContrastCardiome Pharma (CRME) vs. Fortress Biotech (FBIO) Critical Contrast
www.americanbankingnews.com - March 16 at 12:30 PM
Fortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate HighlightsFortress Biotech Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 16 at 10:04 AM
Checkpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate HighlightsCheckpoint Therapeutics Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
finance.yahoo.com - March 15 at 4:42 PM
Fortress Biotech to Present at Oppenheimers 28th Annual Healthcare Conference - GlobeNewswire (press release)Fortress Biotech to Present at Oppenheimer's 28th Annual Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - March 13 at 10:53 AM
Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition - GlobeNewswire (press release)Mustang Bio to Present at the 255th American Chemical Society National Meeting & Exposition - GlobeNewswire (press release)
globenewswire.com - March 13 at 10:53 AM
Fortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare ConferenceFortress Biotech to Present at Oppenheimer’s 28th Annual Healthcare Conference
finance.yahoo.com - March 13 at 10:53 AM
Fortress Biotech (FBIO) Upgraded at BidaskClubFortress Biotech (FBIO) Upgraded at BidaskClub
www.americanbankingnews.com - March 11 at 2:37 PM
Checkpoint Therapeutics (CKPT) Prices 4.6M Common Stock Offering at $4.35/ShareCheckpoint Therapeutics (CKPT) Prices 4.6M Common Stock Offering at $4.35/Share
www.streetinsider.com - March 8 at 10:31 AM
Fortress Biotech (FBIO) Set to Announce Earnings on WednesdayFortress Biotech (FBIO) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - March 7 at 1:50 AM
B. Riley Weighs in on Fortress Biotech Incs FY2017 Earnings (FBIO)B. Riley Weighs in on Fortress Biotech Inc's FY2017 Earnings (FBIO)
www.americanbankingnews.com - March 5 at 1:10 AM
Fortress Biotech (FBIO) Upgraded at ValuEngineFortress Biotech (FBIO) Upgraded at ValuEngine
www.americanbankingnews.com - March 4 at 6:42 PM
Fortress Biotech (FBIO) Now Covered by Analysts at B. RileyFortress Biotech (FBIO) Now Covered by Analysts at B. Riley
www.americanbankingnews.com - February 28 at 11:54 PM
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of ... - GlobeNewswire (press release)Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of ... - GlobeNewswire (press release)
globenewswire.com - February 27 at 4:45 PM
Fortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene TherapiesFortress Biotech Announces Aevitas Therapeutics Enters Sponsored Research Agreement with the University of Massachusetts Medical School to Advance AAV Gene Therapies
finance.yahoo.com - February 26 at 9:37 AM
Comparing Fortress Biotech (FBIO) & Syros Pharmaceuticals (SYRS)Comparing Fortress Biotech (FBIO) & Syros Pharmaceuticals (SYRS)
www.americanbankingnews.com - February 25 at 1:18 PM
Fortress Biotech Inc (FBIO) Receives Consensus Rating of "Hold" from AnalystsFortress Biotech Inc (FBIO) Receives Consensus Rating of "Hold" from Analysts
www.americanbankingnews.com - February 21 at 10:58 AM
Fortress Biotech (FBIO) Lowered to Sell at Zacks Investment ResearchFortress Biotech (FBIO) Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - February 19 at 10:48 PM
National Holdings Corporation Reports Financial Results for the Fiscal 2018 First QuarterNational Holdings Corporation Reports Financial Results for the Fiscal 2018 First Quarter
finance.yahoo.com - February 15 at 6:37 AM
Fortress Biotech (FBIO) Cut to Sell at Zacks Investment ResearchFortress Biotech (FBIO) Cut to Sell at Zacks Investment Research
www.americanbankingnews.com - February 12 at 11:18 PM
Avenue Therapeutics, Inc. (Nasdaq: ATXI) to Ring The Nasdaq Stock Market Closing BellAvenue Therapeutics, Inc. (Nasdaq: ATXI) to Ring The Nasdaq Stock Market Closing Bell
finance.yahoo.com - February 9 at 3:32 PM
Zacks Investment Research Upgrades Fortress Biotech (FBIO) to "Hold"Zacks Investment Research Upgrades Fortress Biotech (FBIO) to "Hold"
www.americanbankingnews.com - February 6 at 11:06 PM
Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO ... - GlobeNewswire (press release)Avenue Therapeutics to Participate in Panel on Opioid Abuse at BIO ... - GlobeNewswire (press release)
globenewswire.com - February 6 at 3:24 PM
Fortress Biotech (FBIO) and Synlogic (SYBX) Financial SurveyFortress Biotech (FBIO) and Synlogic (SYBX) Financial Survey
www.americanbankingnews.com - February 5 at 9:16 PM
Fortress Biotech (FBIO) Downgraded by Zacks Investment Research to "Sell"Fortress Biotech (FBIO) Downgraded by Zacks Investment Research to "Sell"
www.americanbankingnews.com - January 31 at 11:58 PM
Financial Comparison: Fortress Biotech (FBIO) and Transition Therapeutics (TTHI)Financial Comparison: Fortress Biotech (FBIO) and Transition Therapeutics (TTHI)
www.americanbankingnews.com - January 21 at 3:26 PM
Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the ... - GlobeNewswire (press release)Avenue Therapeutics Announces Dosing of First Patient in Phase 3 Safety Trial of Intravenous Tramadol for the ... - GlobeNewswire (press release)
globenewswire.com - January 2 at 5:55 PM
Fortress Biotech Inc (FBIO) Receives Average Rating of "Buy" from AnalystsFortress Biotech Inc (FBIO) Receives Average Rating of "Buy" from Analysts
www.americanbankingnews.com - January 2 at 8:26 AM

SEC Filings

Fortress Biotech (NASDAQ:FBIO) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Fortress Biotech (NASDAQ:FBIO) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Fortress Biotech (NASDAQ FBIO) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.